FDA Objects To Claims Based On Retrospective Analysis In BenzaClin Letter
Sponsors should be wary of constructing advertising claims that move beyond the primary findings of a clinical trial
Sponsors should be wary of constructing advertising claims that move beyond the primary findings of a clinical trial